Skip to content

Taysha Gene Therapies, Inc.

TSHA

CIK 0001806310

← back to feed
Revenue (TTM)
$4.29M
+17.3% YoY Q1 May 2026
Net Income (TTM)
−$123.55M
−22.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.38
+5.6% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-2,931.1%
Q1 May 2026
Net Margin
-2,881.4%
Q1 May 2026
Free Cash Flow (TTM)
−$107.32M
Q1 May 2026
Cash
$276.58M
Q1 May 2026
Total Debt
$48.96M
Q1 May 2026
Shares Outstanding
287.36M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings